SCHEMBL9902986

SCHEMBL9902986

CC(C)(C)OC(=O)N1CCOc2c(C3CC3)csc2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
EED O75530 1/20 0.40
RBBP4 Q09028 1/20 0.40
SUZ12 Q15022 1/20 0.40
EZH2 Q15910 1/20 0.40
AEBP2 Q6ZN18 1/20 0.40
RECQL P46063 1/20 0.40
ADORA1 P30542 1/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
THRB P10828 1/20 0.37
PTPN2 P17706 1/20 0.37
PTPN1 P18031 1/20 0.37
PTPN6 P29350 1/20 0.37
NAMPT P43490 1/20 0.37
NR1H2 P55055 1/20 0.37
GPR119 Q8TDV5 3/20 0.36
ALDH1A1 P00352 2/20 0.36
USP30 Q70CQ3 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11893474 0.99 USP2 (0.40) USP2SMN1; SMN2EEDRBBP4SUZ12
SCHEMBL9903677 0.83 USP2 (0.44) USP2SMN1; SMN2EEDRBBP4SUZ12
SCHEMBL9903797 0.81 BRD4 (0.36) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL9902475 0.81 USP2 (0.42) USP2SMN1; SMN2EEDRBBP4SUZ12
Hydrochloric Acid SCHEMBL11893788 0.80 BRD4 (0.35) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL9903878 0.80 USP2 (0.41) USP2SMN1; SMN2EEDRBBP4SUZ12
SCHEMBL9902061 0.79 USP2 (0.43) USP2SMN1; SMN2EEDRBBP4SUZ12
SCHEMBL3279440 0.77 MAPK1 (0.47) USP2SMN1; SMN2RECQLNAMPTNR1H2
SCHEMBL9903300 0.77 USP2 (0.39) USP2SMN1; SMN2EEDRBBP4SUZ12
SCHEMBL9903147 0.77 USP2 (0.39) USP2SMN1; SMN2EEDRBBP4SUZ12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8916549-B2 Thienooxazepine derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-12-23 US disclosed
EP-2463290-B1 THIENOOXAZEPINE DERIVATIVE TAKEDA PHARMACEUTICAL (JP) 2014-03-05 EP disclosed
US-20120196848-A1 THIENOOXAZEPINE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-02 US disclosed
EP-2463290-A1 THIENOOXAZEPINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2012-06-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196848-A1 THIENOOXAZEPINE DERIVATIVE HTR2C, HTR2B, HTR2A USP2 3930/4885SMN1; SMN2 3302/4885EED 2484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.